# NovaGen Group - Curation > NovaGen Group aims to change the trajectory of human ageing with treatments designed to restore immune function and slow age-related decline. Through… - Full showcase: https://ai.curationcorp.com/showcase/NovaGen-Group-42219 - Tags: Healthcare, EUROPE, Small - Last updated: 2026-11-11 ## Overview NovaGen is a longevity company combining a premium clinic model, a cell rejuvenation technology, research originating at UCLA and an AI health platform, now pursuing a Nasdaq listing through a proposed merger with VEEA. The core offer is a personalised clinic programme, priced up to €100,000, built around the client's own cells. A small skin sample is taken, the cells are grown in the laboratory and conditioned to reset the chemical marks of ageing, using no viruses and no gene editing, before being used in a treatment overseen by the client's clinician. Over 1,000 people have been through it over the last seven years, while rivals valued in the billions have treated almost none. The science comes from a former tenured UCLA professor, working alongside a team of experienced executives who have successfully led and listed companies before. The same technology is now in development for treatments for ALS, Alzheimer's, osteoarthritis and autoimmune disease, all markets with significant commercial potential. Several things are converging that make now an interesting time to look at NovaGen. Regulators cleared a first formal ALS trial, the clinic model is set to roll out in new countries on a smaller format built to open quickly, and the proposed VEEA merger would bring a US listing and a household health hub to expand client care, with the merger agreement and first hub deployments targeted for Q4 2026. The company's own model has group revenue building from 2027, driven mainly by its clinics, with licensing deals with drug companies layered on top as the disease programmes advance. ## Bull case - **A Global Platform Within a Huge Longevity Industry:** Combination of a scalable clinic model, cell therapy and client data in a growing sector supported by ageing demographics and increasing awareness. - **Clients Already Treated, with a Clear Path to Scale:** Over 1,000 clients treated so far, while rivals valued in the billions have treated almost none. - **Leading Science Run by World-Class Team of Experts:** UCLA-derived research using a client's own cells, no gene editing, led by a top-cited scientist has potential to address several serious diseases. - **Proposed Merger Brings a Nasdaq Listing and Further Health Technology:** VEEA brings secure edge infrastructure that keeps health records, wearable data and biological readings under the client's own control. ## Bear case - **The Evidence Is the Company's Own:** Reported results are exploratory and not independently verified, by NovaGen's own admission. - **Formal Trials Are at an Early Stage:** Only ALS has an approved trial, and it has yet to start. - **The Listing Is Not Yet Finalised:** The VEEA merger is still to complete. ## Key risks - **The Evidence Is the Company's Own:** The figures behind NovaGen's case come from the company itself, not from independent studies. Its own disclosures state that the clinical and biomarker data were supplied by its chief science officer and collaborators, “have not been independently verified”, and were gathered in compassionate-use and exploratory settings rather than the controlled trials that regulators rely on. None of the headline results have yet appeared in a peer-reviewed journal, and biological age tests are not standardised. Until independent evidence shows the process improves health outcomes, not just laboratory markers, the central promise has yet to be confirmed. - **Formal Trials Are at an Early Stage:** Only one programme, ALS, has approval to start a formal trial. The trial is due to start soon and, as an early-stage study, will mainly test safety, so meaningful results are likely years away. Tighter local rules could also limit where partner clinics can offer the longevity treatment. - **The Listing Is Not Yet Finalised:** The merger with VEEA is based on a non-binding term sheet. VEEA itself is small and financially stretched, with under $1m of cash and more than $13m of debt at its last report. ## Catalysts - Definitive merger agreement: Signing the binding deal with VEEA would clear the biggest condition over the story. A term sheet was signed in September 2026. Health platform launch: NovaGen Health Networks is due to start rolling out at clinics and partner hospitals from late 2026. That would give the AI platform its first real users. ALS trial start : the approved ALS trial is due to begin soon. - ALS trial results : First safety results from the ALS trial would be the first steps towards evidence that regulators recognise. Clinic expansion : The company plans a US clinic in 2027, alongside sites in Serbia and in the Middle East. Each new clinic would add revenue and bring more clients into the dataset. - Independent proof: Results published in peer-reviewed journals, or approval from a Western regulator, would answer the biggest question over NovaGen and could open the door to pharmaceutical partnerships. New revenue streams: Cell banking, diagnostics and licensing are designed to earn money without waiting for a therapy to be approved. That would make income steadier and less dependent on any single trial ## Highlights - **A Global Platform Within a Huge Longevity Industry:** The longevity sector has attracted enormous sums of money despite being at a very early stage. Altos Labs launched with $3bn from backers including Jeff Bezos, Sam Altman has personally put around $180m into Retro Biosciences, and Gulf sovereign funds are assembling multi-billion healthspan strategies. The company points to a longevity biotech market of €72.6bn, an anti-ageing market of €150bn, and regenerative medicine growing at nearly 12% a year to 2033, against a world where the over-60 population is set to roughly double by 2050. Few of the companies chasing that have anything to sell. NovaGen is different because its protocol already has a track record with paying clients. Built on top of that are the ambitions that make it more than a wellness business: treatments for serious age-related disease, and a data platform designed to hold each client's health record for life, both of which present a large commercial opportunity. - **Clients Already Treated, with a Clear Path to Scale:** Over 1,000 people have been treated with the protocol over seven years, the company says. Expansion is targeted through two models, with luxury flagships building credibility, while compact urban clinics are designed to open quickly across major cities, moving from Europe into MENA, Asia and North America. The company believes this strategy will allow group revenue to build from 2027 towards roughly €744m by 2035, driven mainly by clinic income. Eight further business lines sit on top, from personal cell banking to diagnostics and licensing. These are the company's projections, based on its own assumptions. - **Leading Science Run by World-Class Team of Experts:** Their proprietary process takes a small skin sample to yield the client's own fibroblasts, which are expanded and conditioned with small molecules over a period of several months. No viruses, no gene editing and no donor cells are used. The process uses partial cellular reprogramming, designed to avoid the risks associated with complete reprogramming. Using the client's own cells minimises the risk of immune rejection associated with donor-derived therapies. The same technology is also being applied beyond longevity, with programmes in ALS, Alzheimer's, osteoarthritis and autoimmune disease, led by an approved ALS trial. Two patents have been granted with a third pending, covering three of those diseases, and the manufacturing method is kept as a trade secret, making it harder for rivals to replicate. Chief science officer Prof Yi Eve Sun is a former tenured UCLA professor with more than 140 published papers, including in Nature, Science and Cell, the field's most selective journals. Around her sit executives who have founded, scaled and exited life sciences businesses before, providing commercial expertise alongside the science. - **Proposed Merger Brings a Nasdaq Listing and Further Health Technology:** In September 2026 a term sheet was signed to combine with Nasdaq-quoted VEEA, with a definitive agreement targeted for Q4 2026. This is important for two key reasons. The first is a route to a US market without the cost and delay of a conventional flotation. The second is VEEA's edge computing, which processes sensitive medical data inside the home rather than shipping it to a distant cloud. It underpins NovaGen Health Networks, a household hub giving each family member a digital twin and a records wallet under their own control, with first deployments at clinics and partner hospitals due before the end of 2026. Clinician-supervised diagnostics and therapy pathways follow as validation and approvals allow. ## Frequently asked questions ### Where Does the Revenue Come From, and Where Could It Go? The model is built mainly around clinics. Clients pay up to €100,000 for a personalised longevity programme. The company's own model, which is unaudited and depends on clinical and regulatory outcomes, projects group revenue building from 2027 to roughly €744m by 2035, driven mainly by clinic income. Eight further lines are planned on top, including personal cell banking, diagnostics, consumer products and licensing. Clinic revenue is the engine, with the other lines designed to layer onto an existing client relationship rather than replace it. ### What Sets NovaGen Apart in the Longevity Market? Most longevity clinics buy in their treatments. NovaGen owns the science behind its own, with two patents granted and a third pending, and the manufacturing method kept secret rather than published. The contrast with the research-led competitors is sharper still. Altos Labs and NewLimit have between them raised billions but have yet to report treating anyone, while Retro Biosciences is running its first safety trial in healthy volunteers, recently expanded to 108 participants. NovaGen reports over 1,000 treated over seven years. The figures are the company's own, but they suggest a treatment track record well ahead of the research-led competitors. ### Who Leads the Company? Chief executive Diederik van der Reijt has an exit from Kokomo Capital behind him and co-founded NKore Biotherapeutics, the UCLA spinout that connects him to the science. Chief science officer Prof Yi Eve Sun is a former tenured UCLA professor and a top-cited researcher in stem cell biology. Chief medical officer Dr Henk Viëtor has co-founded more than 20 life sciences companies, and chief growth officer Karen Brink has run several US listing processes. For a company of this size, that is an unusual depth of public-market experience. ### What Does a Client Receive in a Clinic? A skin sample of roughly one square centimetre is taken under local anaesthetic. The laboratory isolates fibroblasts, the workhorse cells of skin, expands them into a large batch and conditions them with small molecules, a process that takes several months. It uses partial cellular reprogramming, designed to avoid the risks associated with complete reprogramming. No viral vectors, no gene editing and no donor cells are involved, and using the client's own cells minimises the risk of immune rejection associated with donor-derived therapies. How the material is then used and followed up is a matter for licensed clinicians under local rules. ### What Are the Key Milestones Ahead? The VEEA merger needs to convert from a term sheet into a signed agreement, which would deliver the Nasdaq quote after the merger. The clinic rollout needs to show that a compact urban site can earn like a flagship, since the revenue model multiplies sites rather than growing any one of them. And the ALS trial needs to start, progress and report, giving the science its first evidence gathered to standards a Western regulator recognises. The signed agreement is targeted for Q4 2026. ### What Does the VEEA Merger Bring to NovaGen? Two things: data, and a listing. VEEA builds technology that processes information locally rather than sending it to a distant cloud, which matters when the information is medical. Combined with NovaGen's clinic model, that produces NovaGen Health Networks: a household hub holding records, wearable readings and biological measurements under the client's control, with a digital twin for each family member. Phase 1 launches in late 2026, and clinician-supervised diagnostics and therapy pathways follow as validation and approvals allow. The merger also supplies an existing Nasdaq quote, reached without the cost and delay of a conventional flotation. ## Disclosure NovaGen Group is a client of Curation and pays for this showcase. This is information, not investment advice. Capital is at risk.